IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2024 | $12.00 | Buy | Rodman & Renshaw |
| 10/30/2024 | $12.00 | Buy | H.C. Wainwright |
| 9/24/2024 | $12.00 | Buy | Maxim Group |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
Fastest customizable press release news feed in the world
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has submitted a new patent application with the U.S. Patent and Trademark Office (USPTO) titled "Spheroids For Cartilage Repair" covering a proprietary fibroblast-derived therapy platform for use in orthopedic and musculoskeletal conditions, including degenerative disc repair, cartilage repair, and joint restoration. The application, if gr
HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has paid all amounts outstanding under the convertible promissory notes (the "Notes") issued to YA II PN, Ltd. ("Yorkville"), an investment fund managed by Yorkville Advisors Global, LP, pursuant to the Standby Equity Purchase Agreement ("SEPA") entered into on December 20, 2024 between the Company and Yorkville. The SEPA allows the Compan
HOUSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 4,477,614 shares of its common stock at an offering price of $0.335 per share of common stock. Additionally, in a concurrent private placement, the Company issued and sold unregistered warrants to purchase up to an aggregate
HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 4,477,614 shares of its common stock at an offering price of $0.335 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company will issue and sell unregistered wa
HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has received both public and private Human Research Ethics Committee (HREC) approvals in Australia for a Phase 1/2 clinical trial evaluating CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers (DFU). This approval enables enrollment of 120 patients at 10 sites across Australia. With the HREC approval and Therapeutics Goods Administration (TGA) fili
HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced issuance and sale to an existing shareholder of 3,540,000 shares of its common stock and pre-funded warrants to purchase 8,570,203 shares of its common stock at a purchase price of $0.3303 per share or pre-funded warrant (less $0.00001 for each pre-funded warrant), in a registered direct offering priced at-th
HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has entered into a definitive agreement for the issuance and sale to an existing shareholder of 3,540,000 shares of its common stock and pre-funded warrants to purchase 8,570,203 shares of its common stock at a purchase price of $0.3303 per share or pre-funded warrant (less $0.00001 for each pre-funded warrant), in a registered direct offering p
Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients Preparing to submit Investigational New Drug applications for the treatment of psoriasis with CYPS317 and the treatment of multiple sclerosis with CYMS101 HOUSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced third quarter
HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the Bio-Europe 2025 conference taking place November 3-5, 2025, at the Vienna Congress and Convention Center in Vienna, Austria. FibroBiologics will deliver a company presentation at 4:15 p.m. CET on Tuesday, November 4, and will be available for one-on-one investor meetings throughout the ev
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the 2025 ThinkEquity Conference taking place October 30 at the Mandarin Oriental in New York City. FibroBiologics will deliver a company presentation at 4:30 p.m. ET on October 30 and will be available for one-on-one investor meetings throughout the event. For more information, please visit
D - FibroBiologics, Inc. (0001958777) (Filer)
D - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
424B5 - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
10-Q - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
10-Q - FibroBiologics, Inc. (0001958777) (Filer)
8-K/A - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
3 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
Live Leadership Updates
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update. Recent Highlights Successfully closed third $5 million tranche of a $25 million total financing, with proceeds used to advance research and development efforts and support the upcoming Phase 1/2 clinical trial in diabetic foot ulcers (DFUs).Strengthened leadership team with the appointment of
HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologic
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b
HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel. He will report to Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer, and be an integral member of the executive leadership team. "The addition of Ruben as our General Counsel rep